AR122143A1 - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- AR122143A1 AR122143A1 ARP210101387A ARP210101387A AR122143A1 AR 122143 A1 AR122143 A1 AR 122143A1 AR P210101387 A ARP210101387 A AR P210101387A AR P210101387 A ARP210101387 A AR P210101387A AR 122143 A1 AR122143 A1 AR 122143A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- substituents
- formula
- rings
- optionally further
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos que presentan acción antagonista del receptor de GPR139, por ejemplo, compuestos de la fórmula (1) y sales farmacéuticamente aceptables de estos, composiciones farmacéuticas que comprenden estos, y métodos para tratar enfermedades mediadas por el receptor de GPR139, por ejemplo, depresión, enfermedad de Alzheimer, esquizofrenia, adicción a fármacos, trastornos del sueño, dolor, y trastorno por déficit de atención con hiperactividad, mediante el uso de estos. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable de este, en donde: R¹ es un compuesto de fórmula (2) o (3); el anillo A¹ se elige de anillos aromáticos de 6 miembros opcionalmente sustituidos adicionalmente; el anillo A² se selecciona de anillos heterocíclicos aromáticos monocíclicos de 5 miembros opcionalmente sustituidos adicionalmente; el anillo B se selecciona de anillos de piridona opcionalmente sustituidos con 1 a 3 sustituyentes adicionalmente elegidos de átomos de halógeno y grupos C₁₋₆ opcionalmente sustituidos; R² y R³ se seleccionan cada uno independientemente de un átomo de hidrógeno y sustituyentes; R⁴ᵃ y R⁴ᵇ se seleccionan cada uno independientemente de los sustituyentes; y el anillo C se selecciona de anillos heterocíclicos aromáticos monocíclicos de 5 miembros opcionalmente sustituidos adicionalmente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020090111A JP2021183587A (ja) | 2020-05-22 | 2020-05-22 | 複素環化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122143A1 true AR122143A1 (es) | 2022-08-17 |
Family
ID=76797026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210101387A AR122143A1 (es) | 2020-05-22 | 2021-05-20 | Compuestos heterocíclicos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230357220A1 (es) |
EP (1) | EP4153581A1 (es) |
JP (2) | JP2021183587A (es) |
KR (1) | KR20230015946A (es) |
CN (1) | CN116171276A (es) |
AR (1) | AR122143A1 (es) |
AU (1) | AU2021276623A1 (es) |
BR (1) | BR112022023503A2 (es) |
CA (1) | CA3178798A1 (es) |
IL (1) | IL298275A (es) |
MX (1) | MX2022014576A (es) |
TW (1) | TW202208346A (es) |
WO (1) | WO2021234451A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202206054D0 (en) * | 2022-04-26 | 2022-06-08 | Cerevance Ltd | Novel Compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE298765T1 (de) | 1996-08-27 | 2005-07-15 | Praecis Pharm Inc | Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren |
DE19736352C1 (de) | 1997-08-21 | 1998-12-10 | Atotech Deutschland Gmbh | Vorrichtung zur Kontaktierung von flachem Behandlungsgut in Durchlaufgalvanisieranlagen |
CA2374346C (en) | 1999-06-28 | 2010-06-22 | Jordan J. N. Tang | Inhibitors of memapsin 2 and use thereof |
WO2020097609A1 (en) * | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
JP2020090111A (ja) | 2018-12-03 | 2020-06-11 | パイオニア株式会社 | 発光システム |
-
2020
- 2020-05-22 JP JP2020090111A patent/JP2021183587A/ja active Pending
-
2021
- 2021-05-20 KR KR1020227044430A patent/KR20230015946A/ko active Search and Examination
- 2021-05-20 MX MX2022014576A patent/MX2022014576A/es unknown
- 2021-05-20 JP JP2022570532A patent/JP2023528281A/ja active Pending
- 2021-05-20 CN CN202180059093.3A patent/CN116171276A/zh active Pending
- 2021-05-20 EP EP21737769.6A patent/EP4153581A1/en active Pending
- 2021-05-20 CA CA3178798A patent/CA3178798A1/en active Pending
- 2021-05-20 AR ARP210101387A patent/AR122143A1/es unknown
- 2021-05-20 AU AU2021276623A patent/AU2021276623A1/en active Pending
- 2021-05-20 IL IL298275A patent/IL298275A/en unknown
- 2021-05-20 US US17/999,514 patent/US20230357220A1/en active Pending
- 2021-05-20 BR BR112022023503A patent/BR112022023503A2/pt unknown
- 2021-05-20 TW TW110118337A patent/TW202208346A/zh unknown
- 2021-05-20 WO PCT/IB2021/000337 patent/WO2021234451A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP4153581A1 (en) | 2023-03-29 |
MX2022014576A (es) | 2023-02-14 |
TW202208346A (zh) | 2022-03-01 |
IL298275A (en) | 2023-01-01 |
BR112022023503A2 (pt) | 2023-01-17 |
CA3178798A1 (en) | 2021-11-25 |
KR20230015946A (ko) | 2023-01-31 |
WO2021234451A1 (en) | 2021-11-25 |
AU2021276623A1 (en) | 2022-12-22 |
JP2023528281A (ja) | 2023-07-04 |
CN116171276A (zh) | 2023-05-26 |
US20230357220A1 (en) | 2023-11-09 |
JP2021183587A (ja) | 2021-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
PE20230238A1 (es) | Inhibidores de kras g12c | |
PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
JP5615902B2 (ja) | イミダゾ[2,1−b][1,3,4]チアジアゾール誘導体 | |
AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
AR097024A1 (es) | Derivados sustituidos de quinazolin-4-ona | |
CY1105035T1 (el) | Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες | |
AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
BRPI0607600A2 (pt) | derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina | |
AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
PE20210477A1 (es) | Derivado policiclico de carbamoilpiridona | |
AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
AR067904A1 (es) | Derivados de piperazina-amida | |
AR119234A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
AR051686A1 (es) | Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4. | |
AR065863A1 (es) | Derivados de imidazolidinona | |
EP2970223A1 (en) | Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use | |
AR120377A1 (es) | Derivados heteroaromáticos de sulfiliminas o sulfoximinas con actividad fungicida | |
PE20160284A1 (es) | Derivados de amida como antogonistas del receptor de acido lisofosfatidico | |
AR118983A1 (es) | Antagonistas cíclicos del receptor b2 de bradiquinina | |
AR122143A1 (es) | Compuestos heterocíclicos | |
PE20080191A1 (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 | |
ECSP21037191A (es) | Pirazoles como moduladores de la hemoglobina |